04 March 2021
R&D Center NovaMedica Innotech (subsidiary of the pharmaceutical company NovaMedica, investment project of RUSNANO) announced release of the first commercial batch of the anti-COVID drug Avifavir® under the partnership with Kromis LLC, joint venture of the Russian Direct Investment Fund (RDIF) and the company ChemRar. NovaMedica Innotech will manufacture 100,000 units of Avifavir per month.
03 March 2021
We have already made a tradition of guided tours to the R&D Center NovaMedica Innotech for our most curious and precious visitors – children who come to see what their mothers and fathers do at work.
24 December 2020
NovaMedica team wishes you Happy Holidays! Harmony and joy to you and your loved ones. We wish you to be cheerful and healthy, creative and enthusiastic!
04 December 2020
Rustam Iksanov, Vice President for R&D at NovaMedica, believes one of the most important trends in development of the modern pharmaceutical market to be supergenerics. He spoke about this in his address at the Russian Pharmaceutical Forum in Moscow.
01 December 2020
24-25 ноября Институт Адама Смита провел важнейшее для российской фарминдустрии мероприятие – Российский фармацевтический форум. Одну из наиболее важных панелей Форума – «ФАРМАЦЕВТИКА БУДУЩЕГО В РОССИИ И В МИРЕ: ГЛОБАЛЬНЫЙ ВЗГЛЯД НА ТРАНСФОРМАЦИЮ ОТРАСЛИ» - модерировала гендиректор НоваМедики Елена ЛИТВИНОВА. Она поделилась своими впечатлениями о ходе дискуссии и о проблемах отрасли, которые вскрыл ФармФорум.
15 September 2020
Four top managers of the pharmaceutical company NovaMedica were named among the business leaders in the annual Top 1000 Russian Managers rating published by the Russian Managers Association and the Kommersant Publishing House.
20 March 2020
Health and safety of patients, our employees and their families take the highest priority for NovaMedica. As the COVID-19 situation is developing rapidly, we follow the recommendations of the federal and local authorities to prevent the infection from spreading. On March 19, NovaMedica started operating remotely.
20 November 2019
Russian pharmaceutical company NovaMedica announces the appointment of Marina Egorova, formerly director of business development, as head of the company’s commercial unit. Yulia Sobakina, who was in charge of commerce and marketing at NovaMedica since November 2017, will move on to assume the position of commercial director at Magnit Pharma LLC.
25 October 2019
Russian pharmaceutical company NovaMedica announces the appointment of the Vice President for Business Development Elena Litvinova to the position of its CEO. Alexander Kuzin, who was the head of NovaMedica since June 2015, has moved on to work for Pharmacy Chain 36.6 where he will take charge of the retail segment.
25 July 2019
Russian pharmaceutical company NovaMedica and US-based Unipharm have launched a joint project to localize in Russia the production of Melaxen®, a drug that improves the sleep/wake cycle. Volumes are expected to reach hundreds of thousands of units per year, which will be sufficient to fully meet the needs of patients living in the territory of the EAEU.
16 April 2021
16 April 2021
15 April 2021
15 April 2021